Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tivozanib + paclitaxel versus placebo + paclitaxel in recurrent or metastatic triple-negative breast cancer
2012-003507-35Phase 2Terminated
- Sponsor
- AVEO Oncology
- Start
- Mar 2013
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tivozanib, paclitaxel in triple-negative breast cancer (TNBC), breast cancer, sponsored by AVEO Oncology. Started Mar 2013; status: terminated.
02
Drugs
tivozanibpaclitaxel
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on 2012-003507-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003507-35.